Have a feature idea you'd love to see implemented?
Let us know!
IDYA IDEAYA Biosciences Inc
Price (delayed)
$29.2
Market cap
$2.47B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.19
Enterprise value
$2.28B
IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates
Highlights
IDEAYA Biosciences's equity has surged by 86% YoY
The company's debt fell by 27% YoY and by 22% QoQ
The net income has plunged by 107% YoY and by 19% from the previous quarter
The company's gross profit has shrunk by 74% YoY and by 23% QoQ
Key stats
What are the main financial stats of IDYA
Market
Valuations
Earnings
Shares outstanding
84.48M
Market cap
$2.47B
Enterprise value
$2.28B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.37
Price to sales (P/S)
190.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
191.03
Revenue
$11.96M
EBIT
-$153.74M
EBITDA
-$149.51M
Free cash flow
-$134.36M
Per share
Balance sheet
Liquidity
EPS
-$2.19
Free cash flow per share
-$1.72
Book value per share
$12.31
Revenue per share
$0.15
TBVPS
$12.49
Total assets
$973.66M
Total liabilities
$42.01M
Debt
$1.87M
Equity
$931.66M
Working capital
$672.44M
Debt to equity
0
Current ratio
17.5
Quick ratio
17.24
Net debt/EBITDA
1.22
Margins
Efficiency
Dividend
EBITDA margin
-1,250.1%
Gross margin
100%
Net margin
-1,285.4%
Operating margin
-1,600.2%
Return on assets
-19.7%
Return on equity
-20.5%
Return on invested capital
-25.6%
Return on capital employed
-16.5%
Return on sales
-1,285.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IDYA stock price
How has the IDEAYA Biosciences stock price performed over time
Intraday
-1.02%
1 week
-4.86%
1 month
-6.92%
1 year
7.16%
YTD
-17.93%
QTD
-7.83%
Financial performance
How have IDEAYA Biosciences's revenue and profit performed over time
Revenue
$11.96M
Gross profit
$11.96M
Operating income
-$191.39M
Net income
-$153.74M
Gross margin
100%
Net margin
-1,285.4%
IDYA's operating income has dropped by 126% year-on-year and by 20% since the previous quarter
The net income has plunged by 107% YoY and by 19% from the previous quarter
The company's gross profit has shrunk by 74% YoY and by 23% QoQ
The revenue has dropped by 74% year-on-year and by 23% since the previous quarter
Growth
What is IDEAYA Biosciences's growth rate over time
Valuation
What is IDEAYA Biosciences stock price valuation
P/E
N/A
P/B
2.37
P/S
190.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
191.03
The EPS has declined by 47% year-on-year and by 9% since the previous quarter
IDEAYA Biosciences's equity has surged by 86% YoY
The stock's P/B is 28% below its last 4 quarters average of 3.3
The revenue has dropped by 74% year-on-year and by 23% since the previous quarter
The stock's price to sales (P/S) is 27% more than its last 4 quarters average of 149.5
Efficiency
How efficient is IDEAYA Biosciences business performance
The return on sales has dropped by 55% since the previous quarter
The ROA has contracted by 13% YoY and by 2.1% from the previous quarter
IDYA's ROIC is down by 7% YoY
The company's return on equity fell by 7% YoY
Dividends
What is IDYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IDYA.
Financial health
How did IDEAYA Biosciences financials performed over time
IDEAYA Biosciences's total assets has surged by 85% YoY
IDEAYA Biosciences's total liabilities has soared by 62% YoY and by 60% from the previous quarter
The company's debt is 100% lower than its equity
IDEAYA Biosciences's debt to equity has shrunk by 100% YoY
IDEAYA Biosciences's equity has surged by 86% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.